Across TCGA pan-cancer cohorts, LINC00691 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LINC00691’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where LINC00691 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC00691 is over-expressed in tumor, although a few such as THCA and KIRP show the opposite, repressed pattern.

BLCA, HNSC, and LIHC are the cancer types where LINC00691 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC00691 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.078	.001	7	view →
HNSC	Male	IV	+0.049	.002	7	view →
LIHC	Female	All	+0.012	<.001	5	view →
LUSC	All	All	+0.022	.027	2	view →
THCA	All	All	−0.017	.003	2	view →
KIRP	Male	All	−0.017	.009	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: LINC00691 RNA expression & survival · all LINC00691 data types